Changeflow GovPing Pharma & Drug Safety Hydrazone derivative with aryl-substituted term...
Routine Notice Added Final

Hydrazone derivative with aryl-substituted terminal amine group and use thereof

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

USPTO granted Patent No. US12590071B2 to Korea Institute of Science and Technology on March 31, 2026, covering hydrazone derivatives where the terminal amine group is substituted with aryl or heteroaryl groups. The patent includes 14 claims relating to compounds represented by Formulas 3 and 4, and methods of making these compounds. The patent relates to heterocyclic organic chemistry with potential pharmaceutical applications.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO granted Patent No. US12590071B2 to Korea Institute of Science and Technology on March 31, 2026, for a hydrazone derivative where the terminal amine group is substituted with an aryl or heteroaryl group. The patent contains 14 claims covering compounds represented by Formula 3 and Formula 4, including unsubstituted and substituted benzothiazolyl, quinolinyl, indolyl, pyrrolopyridinyl, and oxodihydrobenzothiazolyl derivatives. The filing date was December 26, 2018, under Application No. 17415382.\n\nThis patent grant establishes enforceable intellectual property rights in the United States for the Korea Institute of Science and Technology. Third parties interested in developing, manufacturing, or commercializing products incorporating these hydrazone derivatives should conduct freedom-to-operate analyses to assess potential infringement risks. The patent does not impose compliance obligations but rather grants exclusive rights that others must respect.

Archived snapshot

Mar 31, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof

Grant US12590071B2 Kind: B2 Mar 31, 2026

Assignee

KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventors

Ae Nim Pae, Yun Kyung Kim, Sang Min Lim, Sungsu Lim, Jihye Seong, Jae Wook Lee, Ji Yeon Song, Seulgi Shin, Hyean Jeong Jeong, Woo Seung Son, Haeun Lee, Da Mi Lim, Seok Kyu Kim, Jee Yun Ahn, Chae Won Kim, Ashwini Machhindra Londhe, Lizaveta Gotina, Hyojin Kim, Hye Yeon Lee, Nam Gyung Kim, Eunji Cha, Kunhee Kim, Ji Woong Lim

Abstract

A compound represented by Formula 3 as described herein, or a pharmaceutically acceptable salt thereof, and a method of making a Formula 3 compound. In Formula 3: R1 is hydrogen; and
Cy is unsubstituted benzothiazol-6-yl, benzothiazol-5-yl, quinolin-3-yl, indolyl, pyrrolopyridinyl, oxodihydrobenzothiazolyl, or oxodihydrobenzoxazolyl; orsubstituted benzothiazol-6-yl, benzothiazol-5-yl, indazolyl, quinolin-3-yl, indolyl, pyrrolopyridinyl, oxodihydrobenzothiazolyl, oxodihydrobenzoxazolyl, or oxodihydrobenzoimidazolyl, each of which is substituted with: (i) methyl, ethyl, propyl, butyl, isopropyl, isobutyl, methoxy, ethoxy, fluoro, chloro, bromo, trifluoroethyl, difluoromethyl, trifluoromethoxy, dimethylcarbamoyl, phenoxy, isopropoxy, methylamino or dimethylamino; or (ii) phenyl, pyridinyl, furanyl, or thiophenyl unsubstituted or substituted with at least one of methyl, fluoro, and dimethylamino.
A compound of Formula 4 as described herein, or a pharmaceutically salt thereof.

CPC Classifications

C07D 241/42 C07D 209/14 C07D 215/38 C07D 231/12 C07D 231/56 C07D 237/14 C07D 239/26 C07D 239/30 C07D 239/34 C07D 277/28 C07D 277/82 C07D 417/04 C07D 417/12 C07D 471/04 C07D 487/04 C07C 255/66

Filing Date

2018-12-26

Application No.

17415382

Claims

14

View original document →

Named provisions

Abstract Claims Formula 3 Formula 4

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
March 31st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12590071B2

Who this affects

Applies to
Pharmaceutical companies Government agencies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Patent Rights
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!